|Title:||Guidelines for treating iron overload in myelodysplastic syndromes: A Taiwan consensus statement||Authors:||BOR-SHENG KO
|Issue Date:||2014||Publisher:||Springer-Verlag Tokyo||Journal Volume:||100||Journal Issue:||1||Start page/Pages:||7-15||Source:||International Journal of Hematology||Abstract:||
Iron overload is common in myelodysplastic syndrome (MDS) patients, and an accumulation of evidence shows that iron chelation may have benefits in these patients. However, discussion and consensus about iron chelation therapy (ICT) for MDS patients is lacking in Taiwan and other Southeast Asian countries. An Expert Panel in Taiwan was organized in 2011 to develop iron overload guidelines and provide a uniform reference for physicians treating MDS patients with iron overload, with specific regard to when to initiate ICT, in which patients, and the clinical and scientific rationale behind its use. ? 2014 The Japanese Society of Hematology.
|ISSN:||0925-5710||DOI:||10.1007/s12185-014-1607-x||metadata.dc.subject.other:||deferasirox; deferoxamine; ferritin; iron; iron chelating agent; ferritin blood level; hematopoiesis; human; iron balance; iron chelation; iron chelation therapy; iron overload; life expectancy; liver biopsy; myelodysplastic syndrome; organ injury; practice guideline; review; survival; chelation therapy; complication; drug effects; iron overload; Myelodysplastic Syndromes; practice guideline; procedures; Taiwan; Chelation Therapy; Hematopoiesis; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Practice Guidelines as Topic; Survival Analysis; Taiwan
|Appears in Collections:||醫學系|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.